JPX and LINC00641 ncRNAs expression in prostate tissue: A case-control study

5Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background and purpose: Prostate cancer (PC) is the second most prevalent cancer in men. Prostate-specific antigen (PSA) is the main biomarker for screening PC. An increase in PSA could lead to false-positive results. Thus, more appropriate markers should be investigated. In the present study, JPX and LINC00641 expression levels were measured in tumoral prostate tissue compared with the non-tumor tissue. Experimental approach: 43 pairs of prostate tumoral and non-tumor tissue were prepared. The expression levels of JPX and LINC00641 were investigated by RT-qPCR. Findings/Results: Significant upregulation of LINC00641 (2.47 ± 0.5 vs 1.41 ± 0.2) and downregulation of JPX (1.42 ± 0.6 vs 2.83 ± 1.0) were observed in PC tissues compared with the normal tissues (their adjacent non-tumoral tissues). Conclusion and implications: Dysregulation of JPX and LINC00641 in PC patients could be used in the future as a prognostic biomarker in PC.

Cite

CITATION STYLE

APA

Sajjadi, R. S., Modarressi, M. H., & Tabatabaiefar, M. A. (2021). JPX and LINC00641 ncRNAs expression in prostate tissue: A case-control study. Research in Pharmaceutical Sciences, 16(5), 493–504. https://doi.org/10.4103/1735-5362.323916

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free